### **IQCP for GENEXPERT**

Ea	~i	litv	,.
га	CI	Hυ	y.

**EXAMPLE** 

#### **Test System:**

Cepheid GeneXpert

### **Test System Primary SOPs include:**

MICROBIOLOGY QUALITY CONTROL MANUAL - BOOK 1

MOLECULAR QUALITY CONTROL MANUAL - BOOK 8

### **Historical Quality Review:**

Regulatory guidelines required testing of external QC with each new lot, every 30 days or with each new shipment. Internal controls are run with each specimen. Each test includes a Sample Processing Control (SPC), a Sample Adequacy Control (SAC) and a Probe Check Control (PCC).

- Sample Processing Control (SPC)—Ensures the sample was correctly processed. The SPC passes if it meets the validated acceptance criteria.
- Sample Adequacy Control (SAC)—Ensures that the sample contains human cells or human DNA. The SAC signal is only to be considered in an analyte negative sample. A negative SAC indicates that no human cells are present in the sample due to insufficient mixing of the sample or because of an inadequately taken sample.
- **Probe Check Control (PCC)**—Before the PCR reaction starts, the GeneXpert instrument measures the fluorescence signal from the probes to monitor bead rehydration, reaction-tube filling, probe integrity and dye stability. PCC passes if it meets the validated acceptance criteria.

The laboratory has been following the **CLSI standards for years without any significant QC problems**. It is rare to encounter an out-of-range result with QC. Processes to mitigate patient reporting errors and delayed reports are addressed in this IQCP.

#### Information Used to Conduct Risk Assessment

## **Regulatory and Accreditation Requirements:**

## **Checklist from Accrediting Agency:**

- CAP IQCP checklist guestions in the ALL COMMON and MICROBIOLOGY checklist
- CMS requirements

### Method verification:

- Instrument received and test system verification completed in 2010.
- Subsequent verifications performed for additional tests added to the menu:

MRSA - 2010

C. difficile – 2010

VRE - 2012

Flu - 2014

Chlamydia and Gonorrhea - 2014

• Documentation filed in Microbiology lab.

## **Training of personnel:**

• Completion of training documented in employee personnel files.

## **Competency Assessment:**

• Employees are annually accessed for current competency. Documentation filed in employee personnel files.

## **Proficiency Testing:**

• All personnel test and review results. Proficiency testing records filed in CAP SURVEY binders.

## **Quality Control:**

• CLIA '88 and CAP requirements for testing of QC.

## **Test System Information:**

## **Manufacturer: Cepheid GeneXpert**

- Package insert contains system performance data and describes testing principle and procedure, QC recommendations, and limitations. Package insert is located supervisor's office and are included with each kit shipment.
- Manufacturer alerts and bulletins are located in the Microbiology Lab.
- Operator's manual including troubleshooting guide is located the Microbiology Lab.

## Summary of in-house data from routine testing of QC strains:

• QC testing was performed according to Molecular Microbiology Quality Control located in BOOK 8.

Review of QC records for all 5 assays for the past 12 months (12/1/14 - 11/30/15) demonstrated:

- 163 results including 30 from MRSA, 26 from VRE and C. difficile, 39 from Flu and 42 from Chlamydia and Gonorrhea
- No external qc failures.
- No internal qc failures

## Summary of in-house data from routine instrument performance checks:

- Instrument checks were done according to SOP
- Review of instrument QC records for the past 12 months and 1 report following scheduled maintenance performed by Cepheid service engineer revealed 2 instrument performance problems that resulted in 2 modules that failed the calibration check. These modules were not in use until replaced on 12-16-15. No patient results were impacted.

#### Risk Assessment and Determination of Risk Level

Frequency of occurrence:

Severity of harm to patient:

Unlikely (once every 2-3 years)

Negligible (temporary discomfort)

Occasional (once per year)

Minor (temporary injury; not requiring medical intervention)

Probable (once per month)

Frequent (once a week)

Serious (impairment requiring medical intervention)

Critical (life threatening consequences)

## **Risk Level:**

Risk level for any Risk Factor that is "Not Acceptable" must be addressed in the IQCP.

Risk level for any Risk Factor that is "Acceptable" may be included in the IQCP at the discretion of the Laboratory Director.

## **Risk Acceptability Matrix**

Probability of Harm	Negligible	Minor	Serious	Critical
Frequent	Not Acceptable	Not Acceptable	Not Acceptable	Not Acceptable
Probable	Acceptable	Not Acceptable	Not Acceptable	Not Acceptable
Occasional	Acceptable	Acceptable	Acceptable	Not Acceptable
Unlikely	Acceptable	Acceptable	Acceptable	Acceptable

## **Risk Acceptability Assignment**

Risk Factor (Possible Sources of Error)	Frequency of occurrence	Severity of harm to patient	Risk Level	
	Preanalytical			
Specimen (Primary):				
Patient identification	probable	minor	Not Acceptable	
Collection/container/volume	frequent	negligible	Not Acceptable	
Integrity	frequent	negligible	Not Acceptable	
Transport	frequent	negligible	Not Acceptable	
Storage	probable	negligible	Acceptable	
Risk Factor	Frequency of	Severity of harm to	Risk Level	
(Possible Sources of Error)	occurrence	patient	RISK Level	

Analytical				
Testing Personnel:				
Training	probable	serious	Not Acceptable	
Competency	probable	serious	Not Acceptable	
Experience	probable	serious	Not Acceptable	
Proficiency Testing	unlikely	negligible	Acceptable	
Staffing	occasional	minor	Acceptable	
Reagents:				
Shipping/receiving/storage	occasional	minor	Acceptable	
Expiration dates	unlikely	minor	Acceptable	
Preparation/use	probable	minor	Not Acceptable	
QC strain storage/prep	occasional	negligible	Acceptable	
Environment:				
Temperature/airflow/humidity/ ventilation	unlikely	negligible	Acceptable	
PCR free	occasional	minor	Acceptable	
Test System:		•		
Mechanical/electronic stability of	occasional	negligible	Acceptable	
instrument/equipment/jam				
Function checks	frequent	serious	Not Acceptable	
Transmission of results to LIS	unlikely	serious	Acceptable	
	Postanalytic	al		
Test Results:				
Transmission of results to Electronic Health Record	occasional	serious	Acceptable	
Review reported results	frequent	serious	Not Acceptable	
Clinician feedback	probable	serious	Not Acceptable	

#### Assessment

Possible Sources of Error	How can identified sources of error be reduced?	

Risk Factor	Possible Error	
	Preanalytical	
1: Specimen - Biological	Improper specimen procurement/ handling/processing	<ul> <li>Adhere to procedures in SOP Phlebotmy.3 that addresses patient identification and specimen collection, labeling, transport, storage and remedial actions to control improperly handled specimens or delayed specimens.</li> <li>Annually review representative specimen processing errors with all staff involved with patient specimens.</li> <li>During initial training and competency assessment, emphasize:</li> <li>Proper specimen handling/processing is the most critical part of any test</li> </ul>
Patient/specimen identification		See above (Specimen)
Collection/container/ volume		See above (Specimen)
Integrity		See above (Specimen)
Transport		See above (Specimen)
Storage		See above (Specimen)
	Analytical	
2: Testing Personnel	Incompletely trained	<ul> <li>During initial training and competency assessment, emphasize:</li> <li>Key aspects of each test.</li> <li>Supervisor annually review any changes in recommendations described by accrediting agencies or standards organizations</li> </ul>
Training		See above (Testing Personnel)
Competency		See above (Testing Personnel)
Experience		Supervisor review reports generated by new employees prior to release for the first two months of their employment
Proficiency Testing		All staff read (and sign off) on PT sample critiques
Staffing	Adequate staff to support the turn-around-times for all shifts.	Supervisor to annually review appropriate staffing needs and schedule staff accordingly
3: Reagents		During initial training and competency assessment, emphasize standard rules to always:

Receiving/storage	<ul> <li>Incorrect ordering</li> <li>Depleted reagent supply</li> <li>Reagent integrity compromised</li> </ul>	<ul> <li>Take responsibility for reagents/supplies (all staff)</li> <li>Maintain reagents at proper storage conditions</li> <li>Check expiration dates</li> <li>Perform required QC</li> <li>Designated staff member(s) assigned to inventory (order/receipt) reagents to ensure inventory properly maintained and testing materials are handled appropriately on receipt</li> </ul>
Expiration dates		See above (Reagents)
QC	QC out of control	<ul> <li>During initial training and competency assessment, emphasize:</li> <li>All specimen-specific QC parameters are controlled within the cartridge; if there is a failure, the assay will not deliver a patient result.</li> <li>Potential sources of QC failures</li> <li>QC troubleshooting</li> <li>QC frequency</li> </ul>
4: Environment	Results not reported (ancillary equipment failure, e.g., bay malfunction)	<ul> <li>Instrument installed at a location following manufacturer's suggestions.</li> <li>During initial training and competency assessment, emphasize standard rules for:</li> <li>Take responsibility for any possible instrument/ environmental problem (out of the ordinary observation)(all staff)</li> <li>Equipment maintenance</li> </ul>
Temperature/airflow/humidity		See above (Environment)
Utilities		See above (Environment)
Space		N/A (sufficient space available)
PCR free		Benches are bleached prior to performing testing; procedures for reducing cross-contamination are used. Also, the test cartridges for the Xpert are self-contained –amplicons cannot escape unless the cartridge integrity is damaged. Proper

		discarding and decontamination protocols are followed for
5: Test System		disposal of all cartridges.  During initial training and competency assessment, emphasize standard rules for:  • Take responsibility for any possible instrument/test system problem (out of the ordinary observation)
Mechanical/electronic/jam	Results not reported (e.g., instrument malfunction and/or aborted test)	<ul> <li>Perform preventive maintenance according to recommended schedule</li> <li>During initial training and competency assessment, emphasize:</li> <li>How to avoid and resolve jams</li> </ul>
Function checks		See above
Transmission of results to LIS	<ul><li>Incorrect transmission of results</li><li>Delay in transmission of results</li></ul>	Daily supervisor (or supervisor designee) review of reported results
		<ul> <li>Annual check of test system- LIS computer interface</li> <li>QA monitor for time to reporting results</li> </ul>
	Postanalytical	
6: Test Results		<ul> <li>Supervisor maintains summary of incorrect results released and meets with laboratory director monthly to review this summary</li> <li>QA monitor for turn-around-times to reporting results</li> <li>During initial training and competency assessment, emphasize:</li> <li>Need for timely results to guide therapy</li> </ul>
Results reported within 5 days	Results delayed beyond that expected	See above (Test Results)
Transmission of results to Electronic Health Record	<ul><li>Incorrect transmission of results</li><li>Delay in transmission of results</li></ul>	See above (Test Results)
Review reported results	Erroneous results reported     Report comments missing	See above (Test Results and Test System) Note: results are checked at multiple steps by tech and then by supervisor
Clinician feedback	Complaints/suggestions regarding delayed results and potential erroneous results	See above (Test Results)  • Incorporate suggestions into QA plan, as appropriate.

### Final QCP for CEPHEID GeneXpert

Based on our risk assessment and Quality Assessment, the QCP consists of following the instructions that are provided in explicit detail in Molecular Quality Control Procedure Manual located in BOOK 8 and are summarized here.

Testing of appropriate QC on each new lot/shipment of panels before or concurrently with placing these materials into use for testing patient's isolates.

Testing of appropriate QC on each panel type monthly.

Testing of appropriate QC on each panel type after major system maintenance or software upgrade before or concurrently with placing the equipment back into service.

Recording and evaluating QC results according to QC acceptability criteria as defined in the SOP. Any out-of-range result is immediately investigated and corrective action performed prior to releasing any patient results.

## Quality Assessment: Ongoing Monitoring for QCP Effectiveness (Performed by supervisor and/or section head)

Reasons for QC failures, PT failures, and patient isolate reporting errors will be examined and addressed as needed in a new/updated risk assessment: 1) Has a new risk factor been identified? 2) Does this change the frequency of risk? 3) Does the risk factor change the potential severity of harm to patient?

Daily review of patient results for reporting errors and clinician complaints. Take corrective action and revise QCP as needed.

Monthly review of QC results by supervisor or section head. Take corrective action and revise QCP when unexpected QC failures indicate adjustment to the QC plan defined herein is needed.

Monthly review of length of time from specimen collection to result reporting to determine incidence of reports delayed. Take corrective action and revise QCP when number of delayed reports exceeds acceptable limit as established by the laboratory director.

Regular review of Proficiency Testing results. Take corrective action and revise QCP if necessary when PT results are not acceptable.

Monthly review of all equipment maintenance/monitoring logs according to standard laboratory protocols. Take corrective action and revise QCP as needed.

Regular training and competency assessment according to standard laboratory protocols. Modify training and revise QCP as needed.

Continual participation in this institution's quality program that addresses specimen handling and erroneous specimen labeling. Take corrective action and revise QCP as needed.

This QCP has been reviewed and is approved	Signature	Date
by the laboratory director (as named on the		
CLIA license).		